Talaris Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Talaris Therapeutics to Neutral from Buy without a price target. The company’s FCR001 clinical programs were discontinued and strategic alternatives being explored, the analyst tells investors in a research note. The firm says it cannot value the company "unless and until there is clarity regarding the strategic alternatives currently being pursued."